Novartis appears set to become a first mover in gene therapy again with the agreed acquisition of AveXis Inc, a company with a late-stage gene replacement therapy for treating spinal muscular atrophy (SMA). ---Subscribe to MedNous to access this article--- Regenerative Medicine Company News Finance, Grants, Deals
